BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chatterjee S, Vardhan B, Singh DK, Maitra A, Ojha UK. Should statins be considered for the management of mucormycosis in COVID-19? Diabetes Metab Syndr 2021;15:102162. [PMID: 34186353 DOI: 10.1016/j.dsx.2021.05.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Azhar A, Khan WH, Khan PA, Al-hosaini K, Owais M, Ahmad A. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach. Journal of Infection and Public Health 2022. [DOI: 10.1016/j.jiph.2022.02.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 García-carnero LC, Mora-montes HM. Mucormycosis and COVID-19-Associated Mucormycosis: Insights of a Deadly but Neglected Mycosis. JoF 2022;8:445. [DOI: 10.3390/jof8050445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Aranjani JM, Manuel A, Abdul Razack HI, Mathew ST. COVID-19-associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic's second wave in India. PLoS Negl Trop Dis 2021;15:e0009921. [PMID: 34793455 DOI: 10.1371/journal.pntd.0009921] [Reference Citation Analysis]